Home » Thought Leadership » Blogs » Page 2

Blogs

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 57 posts
Regulators and HTA Bodies
August 24, 2021 | Blogs, Infographics

Drug Assessment Uncertainties: HTA Bodies vs. Regulators

A recent study of the review of new medicines by regulatory and HTA bodies has revealed areas of misalignment in their processes, highlighting unique challenges in the pathway to patient access.

Cover Image for NRDL Market Access Rare Disease Therapies China 2020 NRDL
August 19, 2021 | Blogs

What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL

The first of two articles investigating market access opportunities in China - CBPartners’ Asia-Pacific Center of Excellence analyzes the opportunities that lie ahead for rare disease products based on 2020 NRDL update inclusion.

CMS Hospital Pricing Transparency
August 2, 2021 | Blogs

CMS Hospital Pricing Transparency: One Price Fits All?

A CMS regulation from the Trump Administration requires hospitals to post lists containing the list price, negotiated private payer prices, and self-pay rates for up to 300 shoppable services took effect in January 2021, with the rule still being widely ignored by hospitals.

Is the Pricing Discount for NRDL Inclusion Worth it? NRDL Commercial Impact Assessment
July 6, 2021 | Blogs

Is the Pricing Discount for Chinese NRDL Inclusion Worth it? NRDL Commercial Impact Assessment

CBPartners Asia Pacific Center of Excellence team have analyzed the dynamics for drug products listed on China’s 2017 NRDL, and subsequent 2018 sales data, to better understand the commercial opportunity within China. Explore the research here.

The-Medical Fund Bill Poland Cover Image
June 2, 2021 | Blogs

Poland’s Medical Fund Bill to Improve Access to Oncology Drugs

The recently introduced Medical Fund Bill has potential to improve access to novel therapies applying for reimbursement in Poland, however, it is yet to be seen how the criteria for inclusion in the Fund’s list are clarified locally and whether a broader scope of therapies will be eligible for the scheme to deem the market more attractive for submissions.